Effects of voluntary exercise on antiretroviral therapy-induced neuropathic pain in mice

Hong Ye 1 • Xingguang Du 1 • Qingli Hua 2

Abstract Antiretroviral therapy (ART) often results in painful peripheral neuropathy. Given that voluntary exercise has been shown to be beneficial in terms of modulating pain-like behaviors in various animal models of peripheral neuropathy, we have investigated the effects of voluntary wheel running on neuropathic pain induced by chronic ART. We first established an animal model of peripheral neuropathy induced by chronic 2',3'-dideoxycytidine (ddC) treatment. We showed that mice receiving ddC (3 mg/kg/day) had increased mechanical and thermal sensitivity at 9 weeks after the onset of the treatment. We also found that voluntary wheel running attenuated or delayed the onset of ddC-induced peripheral neuropathy. This phenomenon was associated with the attenuation of dorsal root ganglion nociceptive neuron membrane excitability and reduction in the expression of the transient receptor potential cation channel subfamily V member 1 (TRPV1). Taken together, these results suggest that voluntary exercise is an effective strategy by which ART-induced peripheral neuropathy can be alleviated.

Keywords Antiretroviral therapy • Peripheral neuropathy • Dorsal root ganglion • Nociceptive neuron • TRPV1

Introduction

Neuropathic pain is reported in 20–40% of patients infected with human immunodeficiency virus (HIV) [1] and seriously affects the patient’s quality of life. Hyperalgesia, allodynia, and spontaneous sensations, such as shooting and burning sensations, are the most common symptoms [2–5]. Antiretroviral therapy (ART) using nucleoside reverse transcriptase inhibitors (NRTIs) and other antiretroviral drugs has been demonstrated to be effective in controlling HIV infection, which has led to ART being widely accepted as first line treatment of HIV/acquired immunodeficiency syndrome (AIDS). However, one of the adverse side effects of ART is the development of painful peripheral neuropathy, as has been reported in about 15–30% of patients using such NRTIs as didanosine, stavudine, and zalcitabine (ddC) [6–8]. The development of painful peripheral neuropathy may lead to the patient discontinuing ART, resulting in worsening of the HIV infection. Many medications, such as antidepressants and topical pain killers, and various new strategies, such as the use of cannabinoid receptor agonists [10], have been used to manage neuropathic pain [9], but there is still a great need for safer non-pharmacological treatments to manage neuropathic pain in HIV-infected patients that have no adverse drug effects.

One possible approach to manage neuropathic pain in this patient population is to introduce physical exercise into the disease management program. Studies have shown that exercise has beneficial effects on the quality of life in HIV/AIDS patients [11], as well as on the relief of chemother-apy-induced pain in cancer patients [12, 13]. In animal models of pain, an extended swimming program has been found to attenuate the development of and to reverse nerve injury-induced thermal and mechanical hypersensitivity in rodents, as well as formalin-induced spontaneous pain in...
rats [14–16]. In addition, voluntary wheel running can decrease paw withdrawal frequency in mouse models of chronic muscle pain [17] and reverse mechanical and visceral hypersensitivity in a high-fat model of prediabetic neuropathy [18]. However, no study has been conducted to date with the aim to examine the effects of voluntary exercise paradigms on ART-induced neuropathic pain.

While the mechanisms underlying the attenuating effects of exercise on pain have not been extensively studied, the results of some studies indicate that physical activities can reduce the hyperexcitability of dorsal root ganglion (DRG) neurons associated with neuropathic pain. Studies on rats have shown that enhanced excitability of the small DRG neurons is associated with bone cancer pain [11]. In animals, injury affecting the axons or their soma in DRGs often causes hyperexcitability that leads to spontaneous firing and neuropathic pain [12, 13]. Enhanced excitability of nociceptive DRG neurons has also been observed in rodent models of inflammatory pain [19, 20]. Therefore, in the present study, we hypothesized that ART-induced neuropathic pain is associated with increased excitability of DRGs and voluntary exercise can alleviate ART-induced neuropathic pain.

Thus, we investigated whether chronic ddC treatment can increase mechanical and thermal sensitivity, indexes of peripheral neuropathic pain [21, 22], and whether repeated voluntary exercise sessions could alter nociceptive thresholds and sensory neuron excitability in a mice model of ART-induced neuropathic pain.

Materials and methods

Animals

Adult C57BL/6 J male mice (n = 84), aged 7–8 weeks at the time of initiation of the experiments, were obtained from the Shanghai Laboratory Animal Center, Shanghai, China. The mice were housed in their home cages under a 12:12 light:dark cycle, at 21–23 °C and 50–60% humidity. Food and water were provided ad libitum. All animal experiments were approved prior to the start of the study by the Institutional Animal Care and Use Committee of Daqing Oil Field General Hospital. The housing and treatment of the rats followed the guidelines of the “Guide for the Care and Use of Laboratory Rats” (Institute of Laboratory Animal Resources, Commission on Life Sciences, 2011).

Animal model of ART-induced neuropathic pain

To establish an animal model of neuropathic pain induced by chronic ART, we administered the antiretroviral drug 2’,3’-dideoxycytidine [zalcitabine (ddC); Sigma-Aldrich, St. Louis, MO] to the mice for 13 weeks. ddC dissolved in normal saline was added to the drinking water (at 0.3–3 mg/kg/day) on the first day of the study. The daily dose corresponds to a standard human dosage (2.25 mg/day for a body weight of 60 kg on average) [23] adjusted for body surface area and was calculated on the basis of a daily water consumption of 5 mL. The ddC-containing water was replaced weekly during regular cage changes. All water bottles that contained ddC were covered with foil to avoid direct light exposure. Observations on fluid consumption, clinical signs and mortality were carried out daily. Body weights were recorded weekly. In general, the mice receiving drinking water supplemented with ddC did not show any signs of dehydration or atypical growth.

Behavioral studies

We conducted all behavioral assays between 8000 and 1700 hours once a week (i.e., always on a Friday). Briefly, prior to testing, mice were acclimated in plexiglass boxes to the testing apparatus for at least 30 min. For all behavioral testing, the experimenter was blinded to treatment conditions. To assess mechanical sensitivity, we also conducted von Frey assays in which mice were first allowed to acclimate on an elevated mesh grid, following which von Frey filaments were applied to the plantar hind paw using the up–down method as described previously [24]. Three trials on each paw were conducted, with a 10-min time interval between trials on opposite paws and a 15-min time interval between trials on the same paw. The average mechanical paw withdrawal thresholds of the three trials on both paws were used to determine the individual mechanical sensitivity. To assess the thermal nociception, we measured the reaction latencies (i.e., first sign of nociception, paw licking, flinching or jump response to avoid the heat) of mice to a hot plate (DL Naturgene Life Science, Beijing, China) at 55 ± 1 °C using a protocol described previously [25]. To avoid damage/injuries to the paws, we used a cut-off period of 20 s.

Voluntary exercise paradigms

Low-profile wireless running wheels were placed in individual cages (Med Associates Inc. Latham, NY) of both control and ddC-treated mice for 2 h (1800–200 hours) each night, 5 nights (Monday–Friday) a week for 13 weeks during the experimental period (duration of ddC treatment 13 weeks; dosage 3 mg/kg/day). Software provided by Med Associates Inc. was used to monitor the running distance. Identical running wheels, but locked, were placed into the cages of the control non-running animals. White noise was provided to modulate external noise during the...
2-h training sessions. When not exercising, animals were housed in groups in their home cages.

**Dissociating DRG neurons**

After the last behavioral testing session, all mice were sacrificed via quick live decapitation. Lumbar (L) DRG (L3–L5) from each mouse were dissected, immediately placed in papain (45 U) and incubated for 30 min. After rinsing and incubation with collagenase (4.5 mg/200 μL) for an additional 30 min, the DRG were triturated to separate the neurons by passage through a 40-μm mesh filter. The dissociated cells were plated on poly-D-lysine/collagen-coated glass coverslips overnight and then tested.

**Electrophysiology**

Whole-cell patch-clamp recordings were made of current generation in cells approximately 20–30 μm in diameter, which increased the likelihood of obtaining recordings from nociceptive neurons. A P-97 micropipette puller (Sutter Instrument Co., Novato, CA) was used to prepare fire-polished glass pipettes with an open tip resistance of about 2.0–7.0 MΩ. Prior to recording, 291-mOsm pipettes were filled with an internal recording solution (120 mM K⁺ gluconate, 0.1 mM CaCl₂, 2 mM MgCl₂, 5 mM NaCl, 10 mM HEPES, 1.1 mM EGTA, 4 mM Na₂ATP, 0.4 mM Na₂GTP, 15 mM phosphocreatine; pH 7.3). During recording, the cells were continuously perfused with an external solution maintained at room temperature (145 mM NaCl, 3 mM KCl, 2.5 mM CaCl₂, 1.2 mM MgCl₂, 10 mM HEPES, 7 mM glucose; adjusted to pH 7.4 with NaOH). For each recording, the series resistance was not higher than 20 MΩ. Patchmaster and the EPC10 USB amplifier (Heka Instruments Inc., Shanghai, China) were used to record the values from neurons. Data analysis was conducted using data from neurons with a resting membrane potential that was more negative than −45 mV.

**Double immunofluorescence staining**

Mice were intracardially perfused with saline followed by 4% paraformaldehyde. L3–L5 DRGs were immediately separated out and post-fixed using 4% paraformaldehyde, followed by submersion in 30% sucrose overnight for cryoprotection. The DRGs were then embedded in optimum cutting temperature compound and rapidly frozen at −20 °C. Frozen tissues were sectioned on a cryostat at a thickness of 15 μm, following which the DRG sections were co-incubated with transient receptor potential cation channel subfamily V member 1 (TRPV1) antibody (1:200; Abcam, Cambridge, UK) in 1% bovine serum albumin and 0.3% Triton-X100 in 0.01 mol/L phosphate-buffered saline (PBS) and one of the following antibodies: anti-neurofilament 200 (NF200) (1:1000; Sigma, St. Louis, MO), fluorescein isothiocyanate-labeled isolectin B4 (IB4-FITC, 10 μg/mL; Sigma), or anti-calcitonin gene-related peptide (CGRP, 1:1000; Sigma) overnight at 4 °C. After washing with PBS, the sections were incubated with rhodamine isothiocyanate (TRITC)-conjugated affinipure goat anti-rabbit immunoglobulin G (IgG; H+L; 1:2000; Jackson Immunoresearch Co., West Grove, PA) and fluorescein isothiocyanate-conjugated goat anti-mouse IgG (H+L; 1:2000; Jackson Immunoresearch Co.), except for IB4, for 40 min at 37 °C. Stained slides were viewed and photographed with a CCD camera under a fluorescent microscope (Leica DM IRB inverted research microscope; Leica Microsystems GmbH, Wetzlar, Germany).

**Statistical analyses**

Data were analyzed using SPSS software (IBM Corp., Armonk, NY) and are presented as the mean ± standard error of the mean. Withdrawal latencies and thresholds were normalized to baseline prior to ART treatment. Repeated-measures analysis of variance (ANOVA) or one-way ANOVA was used, as appropriate. Specifically, to compare mechanical and thermal sensitivity, we used repeated-measures ANOVA, with week as the within-subject factor and treatment as the between-subject factor. DRG neuron membrane potential, spike frequency, spike accounts, and threshold were compared using one-way ANOVA. TRPV1 expression in DRG nociceptive neurons was compared using one-way ANOVA. Data distribution was tested for normality, and ANOVA results were corrected for variance homogeneity and sphericity as needed. In all analyses, a Bonferroni test was used to correct for multiple comparisons. \( P < 0.05 \) was considered to be significant.

**Results**

**Chronic ddC treatment increased mechanical and thermal sensitivity**

The mice on chronic ddC treatment developed peripheral neuropathy. Specifically, after 9 weeks of ddC (3 mg/kg/day) treatment mice exhibited increased mechanical sensitivity (Fig. 1a) and increased thermal sensitivity, as compared with control mice (Fig. 1b).
Chronic ddC treatment increased DRG nociceptive neuron membrane excitability

To determine whether chronic ddC treatment alters membrane and cell excitability properties, we conducted whole-cell patch-clamp electrophysiology on dissociated L3–L5 DRG neuron cultures after completion of the last behavioral tests. Recordings were only conducted on small-diameter neurons (i.e., 20–30 μm diameter; Fig. 2a). Consistent with the results of the behavioral tests, 13 weeks of chronic ddC (3 mg/kg/day) treatment increased the resting membrane potential (Fig. 2c), promoted spike frequency (Fig. 2e) and spike counts (Fig. 2f), and decreased threshold potential (Fig. 2g).

In the whole-cell patch-clamp experiment, step (Fig. 2b) and ramp (Fig. 2d) current injections were used to analyze cell excitability properties. The rheobase was similarly altered in response to either step or ramp current injections by 13 weeks of chronic ddC (3 mg/kg/day) treatment. The results of this experiment showed that both DRG membrane and excitability properties were increased after 13 weeks of chronic ddC (3 mg/kg/day) treatment.

Voluntary wheel running attenuated mechanical and thermal sensitivity after chronic ddC treatment

Those mice which performed voluntary wheel running during the period they received chronic ddC treatment exhibited increased mechanical sensitivity after 11 weeks of ddC (3 mg/kg/day) treatment, as compared with control mice (Fig. 3a). However, mice that performed voluntary wheel running while receiving chronic treatment of ddC exhibited less mechanical sensitivity than mice that did not perform voluntary wheel running (Fig. 3a).

Similarly, during the chronic ddC treatment, mice exhibited increased thermal sensitivity after 9 weeks of ddC (3 mg/kg/day) treatment, as compared with control mice (Fig. 3b). Mice that performed voluntary wheel running during the period of chronic ddC treatment exhibited increased thermal sensitivity after 10 weeks of ddC (3 mg/kg/day) treatment, as compared with control mice (Fig. 3b). However, mice that performed voluntary wheel running during the chronic treatment of ddC exhibited less thermal sensitivity than mice that did not perform voluntary wheel running (Fig. 3b).

Taken together, these results suggest that voluntary wheel running alleviated and delayed the development of peripheral neuropathy after chronic ddC treatment.

Voluntary wheel running attenuated DRG nociceptive neuron membrane excitability after chronic ddC treatment

To determine whether voluntary wheel running alters membrane and cell excitability properties following chronic ddC treatment, we also conducted whole-cell patch-clamp electrophysiology on dissociated L3–L5 DRG neuron cultures after completion of the behavioral tests. Consistent with the results of behavioral testing, 13 weeks
of chronic ddC (3 mg/kg/day) treatment increased resting membrane potential (Fig. 4a), promoted spike frequency (Fig. 4b) and spike counts (Fig. 4c), and decreased threshold potential (Fig. 4d). However, mice that performed voluntary wheel running during the period of chronic treatment of ddC exhibited less membrane excitability properties than did those mice that did not perform voluntary wheel running.

Voluntary wheel running attenuated TRPV-1 expression in DRG nociceptive neurons after chronic ddC treatment

Using specific neuronal markers, we showed that TRPV1 expression was upregulated in specific subtypes of DRG neurons, with TRPV1 expression clearly increased in distinct small DRG neurons. Specifically, TRPV1 increased within CGRP-positive neurons (Fig. 5b) and within IB4-
positive neurons (Fig. 5c), most of which were C-fiber neurons. TRPV1 was not increased in NF200-positive neurons (Fig. 5a), suggesting that myelinated A-fiber neurons may not be involved in the increased expression of TRPV1. These results suggest that it is possible that C-fiber neurons play a great role than A-fiber neurons in the ART-induced expression of TRPV1, since the number of neurons double-stained with CGRP and TRPV1 and with IB4 and TRPV1, respectively, increased after chronic ddC treatment. These effects were reduced by voluntary wheel running.

Discussion

The aim of our study was to investigate the effects of voluntary wheel running on neuropathic pain induced by chronic ART in an animal model of peripheral neuropathy induced by chronic ddC treatment. Our results show that treatment with ddC at 3 mg/kg/day for 13 weeks resulted in increased mechanical and thermal sensitivity in mice at 9 weeks after the onset of the treatment. They also show that voluntary wheel running was able to attenuate or delay ddC-induced peripheral neuropathy, likely due to the attenuative effects of voluntary wheel running on DRG nociceptive neuron membrane excitability via the reduction of TRPV-1 expression. Taken together, we have demonstrated that voluntary exercise is an effective approach to partially alleviate ART-induced peripheral neuropathy.

In our study, we did not focus the effects of voluntary wheel running on nociceptive thresholds of the control animals (i.e., saline chronic treatment). Several previous studies have shown a lack of effects of voluntary exercise on nociceptive thresholds of naïve animals. For example, forced swim training in rats or wheel running in mice in home cage did not alter thermal and mechanical hind paw withdrawal thresholds [16, 17]. Human studies have consistently shown that athletes usually do not exhibit altered basal pain thresholds compared to non-athletes [26, 27]. Thus, we postulate that nociceptive thresholds were likely not altered in the control mice on the chronic saline treatment after voluntary wheel running.

Our findings that physical exercise (i.e., voluntary wheel running) can improve neuropathic pain responses induced by ART are consistent with those of several previous studies. For example, using a rat model, Kuphal et al. reported that 9 days of extended swimming can attenuate formalin-induced spontaneous pain [28]. In animal models of peripheral nerve and spinal cord injury, it has been reported that forced treadmill running can reverse thermal and mechanical hypersensitivity [29–33]. Consistent with these results, it has also been shown that a rigorous treadmill exercise program that was started 1 week before the administration of paclitaxel and continued throughout the treatment can partially alleviate chemotherapy-induced peripheral neuropathy in mice [34]. Furthermore, wheel running can normalize behavioral hypersensitivity associated with pre-diabetic neuropathy [18]. In humans, a recent study showed that a progressive-resisted exercise program has positive effects on health-related quality of life in people suffering from HIV/AIDS-related distal symmetrical poly-neuropathy [35]. The results of our study add to this body of literature, further suggesting that physical exercise may have a broader effect on regulating painful
peripheral neuropathy induced by various pathological processes.

A critical factor that has to be considered in applying an exercise program to pain management is that forced exercise may involve different mechanisms than voluntary exercise. In this respect our study design differed from that of many other published studies in that we used voluntary exercise training as opposed to forced exercise training. It has been reported that forced exercise training is more stressful [36, 37]. For example, Leasure and Jones showed that forced—but not voluntary—wheel running can increase anxiety-like behavior in the open field test [38]. During our experiment, mice were moved in and out of cages which always were equipped with a running wheel, which may have increased the stress level in these animals. While control mice were also placed into cages with locked running wheel cages, environmental changes alone may also increase stress in animals. Therefore, we cannot rule out the effects of stress on mechanical and thermal sensitivity in ddC-treated mice after prolonged wheel running training. In fact, several studies have indicated that voluntary exercise may have anxiolytic effects [39–41]. While pain and anxiety are often associated with each other, few studies have examined the effects of anxiety levels on the regulation of neuropathic pain. Thus, an important aspect of future studies will be to explore whether anxiolytic drugs can promote the effects of voluntary exercise training on reducing ART-induced neuropathic pain.

Notably, exercise intensity also plays a critical role in reducing neuropathic pain in an animal model of neuropathic pain. Specifically, high-intensity exercise has been shown to be more effective than low-intensity exercise in reducing nerve injury-induced mechanical hypersensitivity in rats [31]. In our study, we found that mice which voluntarily used the training wheel (2 h/day) during the 13 weeks of chronic ddC treatment only exhibited partially alleviated neuropathic pain. However, we found no

---

**Fig. 4** Voluntary wheel running reduced ddC treatment-induced increase in DRG neuron membrane excitability properties of mice. Whole-cell patch clamp electrophysiology was performed on small-diameter cultured lumbar DRG neurons (n = 3/mouse). a Resting membrane potential was altered by voluntary wheel running (mean ± SEM; n = 10). b Voluntary wheel running reduced AP frequency (mean ± SEM; n = 10) compared to the saline control group (*P < 0.05) and compared to the running/ddC group (#P < 0.05). c Number of spikes was attenuated (mean ± SEM; n = 10) in the no running/ddC group compared to the saline control group (*P < 0.05) and running/ddC group (#P < 0.05). d AP thresholds for generation of APs, obtained by the phase plot analysis of AP (mean ± SEM; n = 10) Significant difference at *P < 0.05 compared to saline and at #P < 0.05 compared to running/ddC group. Bonferroni correction for multiple comparisons.
correlation between the total running distance (from week 1 to week 13) of individual mice and change in the mechanical paw withdrawal threshold with latency (data not shown). Therefore, it is likely that increasing the intensity of voluntary wheel running (i.e., longer time) in our study would not fully attenuate chronic ddC treatment-induced mechanical and thermal hypersensitivity. Nonetheless, our study indicates that a mild voluntary exercise program can be beneficial to pain management in patients receiving ART.

A number of studies have shown that voluntary exercise can induce physiological adaptations, including increased expression of endogenous opioids and altered expression of growth factors [14, 18, 31, 42–46]. Our study showed that chronic ddC treatment could enhance the expression of TRPV1 in the nociceptive DRG neurons and that voluntary wheel running can attenuate the expression of TRPV1 channels. TRPV1 has been shown to be critically involved in the regulation of mechanical and thermal sensitivity [47–50]. Furthermore, TRPV1 is highly expressed in DRG neurons, and activation of TRPV1 results in sodium and calcium influx, leading to cell depolarization [51, 52]. Therefore, our results suggest that the effects of voluntary exercise on the reduction of ART-induced peripheral neuropathy may be due to the attenuation of the expression of TRPV1 in the nociceptive DRG neurons. Given that studies have also suggested that other TRPV subtypes, such as TRPV4, are also important modulators of mechanical and thermal sensitivity, future studies should determine the role of specific TRPV subtypes in the regulation of ART-induced peripheral neuropathy.

Currently available treatments for neuropathic pain have only modest benefits and, consequently, interventions that prevent the development of neuropathic pain would potentially have a substantial effect on public health [21]. Our study was the first to report the effects of voluntary exercise on ART-induced neuropathic pain. Our results are consistent with those of many previous studies that have shown that voluntary exercise can improve pain-like behavior in various mouse models of peripheral neuropathy. These findings suggest that voluntary exercise may have overlapping mechanisms that contribute to attenuation of distinct types of pain. In fact, it should be noted that peripheral synaptic transmission from DRG neurons to the spinal cord dorsal horn is crucial for pain signaling [53, 54]. These signals are then transferred into the brain for processing the pain sensation and responses [55]. Thus, it is likely that central nervous system (CNS) sensitization due to augmented glutamate neurotransmission underlies the general effects of voluntary exercise on pain. It is important that future studies explore the effects of ART on adaptations in other regions of the CNS and dissect the...
putative role of voluntary exercise in modulations of these ART-induced neuroadaptations. This line of research will not only be important in advancing our knowledge in ART-induced peripheral neuropathy, but it may provide an effective non-pharmacological therapeutic intervention for treating ART-induced painful peripheral neuropathy in HIV/AIDS patients.

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflict of interest.

Research involving human/animal participants All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Funding None.

References

1. Larue F, Fontaine A, Colleau SM (1997) Underestimation and undertreatment of pain in HIV disease: multicentre study. BMJ 314:23–28
2. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM (2003) Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60:1524–1534
3. Pillay P, Wadley AL, Cherry CL, Karstaedt AS, Kamerman PR (2015) Pharmacological treatment of painful HIV-associated sensory neuropathy. S Afr Med J 105:769–772. doi:10.7196/SAMJnew.7908
4. Cherry CL, Wadley AL, Kamerman PR (2012) Painful HIV-associated sensory neuropathy. Pain Manag 2:543–552. doi:10.2217/pmt.12.67
5. Robinson-Papp J, Morgello S, Vaida F, Fitzsimons C, Simpson DM, Elliott KJ, Al-Lozi M, Gelman BB, Clifford D, Marra CM, McCutchan JA, Atkinson JH, Dworkin RH, Grant I, Ellis R (2010) Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy. Pain 151:732–736
6. Fichtenbaum CJ, Clifford DB, Powderly WG (1995) Risk factors for deoxyxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retroviro 10:169–174
7. Moyle GJ, Sadler M (1998) Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 19:481–494
8. Dalakas MC (2001) Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 6:14–20
9. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmiokko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:237–251
10. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL (2007) Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68:515–521
11. Ciccolo JT, Jowers EM, Bartholomew JB (2004) The benefits of exercise training for quality of life in HIV/AIDS in the post-HAART era. Sports Med 34:487–499
12. Wonders KY, Whisler G, Loy H, Holt B, Bohachek K, Wise R (2013) Ten weeks of home-based exercise attenuates symptoms of chemotherapy-induced peripheral neuropathy in breast cancer patients. Health Psychol Res 1(3):e28
13. Mary Collins M, Linda Abbott R, Julie Aschenbrenner R, Connie Hart B (2007) Putting evidence into practice©: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 11:901
14. Almeida C, DeMaman A, Kusuda R, Cadetti F, Ravaneli MI, Queiroz AL, Sousa TA, Zanon S, Silveira LR, Lucas G (2015) Exercise therapy normalizes BDNF upregulation and glial hyperactivity in a mouse model of neuropathic pain. Pain 156:504–513. doi:10.1097/01.j.pain.0000460339.23976.12
15. Kuphal KE, Fibuch EE, Taylor BK (2007) Extended swimming exercise reduces inflammatory and peripheral neuropathic pain in rodents. J Pain 8:989–997. doi:10.1016/j.pain.2007.08.001
16. Shen J, Fox LE, Cheng J (2013) Swim therapy reduces mechanical allodynia and thermal hyperalgesia induced by chronic constriction nerve injury in rats. Pain Med 14:516–525. doi:10.1111/pme.12057
17. Sluka KA, O’Donnell JM, Danielson J, Rasmussen LA (2012) Regular physical activity prevents development of chronic pain and activation of central neurons. J Appl Physiol 114:725–733. doi:10.1152/japplphysiol.01317.2012
18. Groover AL, Rylas JM, Guilford BL, Wilson NM, Christianson JA, Wright DE (2013) Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice. Pain 154:2658–2667. doi:10.1016/j.pain.2013.07.052
19. Shankarappa SA, Piedras-Rentería ES, Stubbs EB (2011) Forced-exercise delays neuropathic pain in experimental diabetes: effects on voltage-activated calcium channels. J Neurochem 118:224–236
20. Chung JM, Chung K (2002) Importance of hyperexcitability of DRG neurons in neuropathic pain. Pain Practice 2:87–97
21. Baron R (2000) Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain 16:S12–S20
22. Höke A (2012) Animal models of peripheral neuropathies. Neurotherapeutics 9:262–269
23. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whittacre C, Mcouliffe VJ (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 334:1011–1018
24. Chapman SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55–63
25. Parvathy SS, Masocha W (2013) Matrix metalloproteinase inhibitor COL-3 prevents the development of paclitaxel-induced hyperalgesia in mice. Med Princ Pract 22:35–41
26. Geva N, Defrin R (2013) Enhanced pain modulation among triathletes: a possible explanation for their exceptional capabilities. Pain 154:2317–2323. doi:10.1016/j.pain.2013.06.031
27. Tesarz J, Schuster AK, Hart B, Gerhardt A, Eich W (2012) Pain perception in athletes compared to normally active controls: a systematic review with meta-analysis. Pain 153:1253–1262. doi:10.1016/j.pain.2012.03.005
28. Kuphal KE, Fibuch EE, Taylor BK (2007) Extended swimming exercise reduces inflammatory and peripheral neuropathic pain in rodents. J Pain 8:989–997
29. Cobianchi S, Casals-Diaz L, Jaramillo J, Navarro X (2013) Differential effects of activity dependent treatments on axonal regeneration and neuropathic pain after peripheral nerve injury. Exp Neurol 240:157–167
